Table 4 Atrial natriuretic (ANP), aldosterone and plasma renin concentration before (baseline) and 11 h (Tmax) after the administration of a single dose of liraglutide and placebo in patients with eGFR < 30 ml/min and > 60 ml/min.

eGFR < 30

Placebo

Baseline^a

74.3

(46.6–91.3)

31.3

(20.2–41.9)

271.6

(267.2–278.9)

Tmax^a

(after 11 h)

78.9

(59.8–119.4)

17.2

(13.2–22.1)

266.5

(255.1–279.9)

p value

(Baseline vs Tmax)

0.31

0.0004

0.003

Liraglutide

Baseline^a

71.6

(50.4–90.8)

29.6

(20.1–45.9)

278.9

(263.3–284.7)

Tmax^a

(after 11 h)

101.2

(87.1–165.8)

16.2

(14.1–20.6)

261.3

(250.4–283.5)

p value

(Baseline vs Tmax)

0.0003

0.0004

0.003

Absolute change after placebo

∆

Placebo^c

2.6

(− 7.2)–(24.4)

− 8.5

(− 23.6)–(− 2.3)

− 9.4

(− 20.7)–(− 0.2)

Absolute change after liraglutide

∆

Liraglutide^c

32.9

(16.4)-(93.5)

− 6.7

(− 19.4)–(− 4)

− 13.8

(− 30.4)–(− 0.4)

p value (liraglutide vs placebo)

0.0003

0.54

0.013

eGFR > 60

Placebo

Baseline^a

56.4

(9.7–94.2)

20

(16.8–34.1)

279.5

(271.5–375.5)

Tmax^a

(after 11 h)

58.9

(13.7–100.7)

18.4

(16.2–27.4)

275.8

(268.9–286.1)

p value

(Baseline vs. Tmax)

0.4

0.0005

0.017

Liraglutide

Baseline^a

57.1

(9.5–95.7)

20.1

(18.9–30.2)

282.6

(277–374.2)

Tmax^a

(after 11 h)

70.5

(16.8–138.1)

19.1

(17.9–29)

279.1

(268.1–285.2)

p value

(Baseline vs. Tmax)

0.003

0.003

0.02

Absolute change after placebo

∆ placebo^c

− 0.2

(− 5.9)–(2.3)

− 1.3

(− 2.9)–(− 0.7)

− 1.9

(− 16.9)–(− 0.4)

Absolute change after liraglutide

∆ liraglutide^c

9.3

(3.4)–(30.8)

− 1.5

(− 2.6)–(− 0.2)

− 2.1

(− 20.2)–(0.9)

p-value (liraglutide vs. placebo)

0.0003

0.36

0.5